2022 Fiscal Year Final Research Report
Elucidation of pathophysiology and development of blood biomarkers focusing on lipid metabolism in interstitial cystitis
Project/Area Number |
20K09566
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 56030:Urology-related
|
Research Institution | Nara Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
藤本 清秀 奈良県立医科大学, 医学部, 教授 (50264867)
可野 邦行 東京大学, 大学院薬学系研究科(薬学部), 助教 (50636404)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 間質性膀胱炎 / 膀胱痛症候群 / 血液バイオマーカー |
Outline of Final Research Achievements |
We enrolled patients with Hunner-type interstitial cystitis (HIC) (n=20), bladder pain syndrome (BPS) (n=20), and overactive bladder (OAB) (n=20) and without lower urinary tract symptoms (controls, n=15). Metabolomics was performed on 323 serum metabolites using liquid chromatography time-of-flight mass spectrometry. The relative areas including anandamide, acylcarnitine (18:2), linoleoyl ethanolamide, and arachidonic acid were smaller in the HIC or BPS group than in the OAB or control group. The differences in the relative areas of anandamide were significant (median: 3.950e-005 and 4.150e-005 vs. 8.300e-005 and 9.800e-005), and the ability to discriminate IC/BPS exhibited an area under the curve of 0.9321. Serum anandamide may be a feasible diagnostic biomarker for IC/BPS. Low serum anandamide levels might be associated with pain and inflammation initiation and may reflect the pathology of IC/BPS.
|
Free Research Field |
排尿障害
|
Academic Significance and Societal Importance of the Research Achievements |
間質性膀胱炎・膀胱痛症候群(IC/BPS)の病態は解明されておらず、診断ならびに治療は確立されていない。診断は、尿意亢進や頻尿などの下部尿路症状を呈する、混同しうる疾患を除外した上で、IC/BPSを疑い、痛みなど強い症状の要因であるハンナ病変の有無を膀胱鏡で確認するという過程である。これには十分な経験が必要で、実臨床では診断が難しい。我々が見出した血清アナンダミドをバイオマーカーとして用いれば、診断における大きな補助となる。また、診断精度の向上は、IC/BPSの病態解明ならびに治療方法開発の促進に寄与する。
|